Exponent price target lowered to $90 from $100 at Truist

Truist lowered the firm’s price target on Exponent (EXPO) to $90 from $100 and keeps a Buy rating on the shares. AI could be a beneficiary to engagements for Exponent as clients turn to the company for failure analysis work, but the firm is also acknowledging the risk that efficiencies could lead to less billable hours and believes that automation will remain an overhang on the consulting industry, the analyst tells investors in a research note.